Exelixis (EXEL) Presents New Data on Cobimetinib Combo Trials in Adv. Melanoma
Tweet Send to a Friend
Exelixis, Inc. (Nasdaq: EXEL) announced the presentation of new data from clinical trials of cobimetinib in combination with other therapies ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
